PRISM BioLab, following its merger with PRISM Pharma (previously PRISM Biolab Corp), founded in 2006, is a biotechnology company focused on developing peptidomimetic small molecules based on cyclic peptides for the potential treatment of cirrhosis, cancer and central nervous system diseases.In October 2018, PRISM Pharma and its wholly-owned subsidiary PRISM BioLab merged, whereby PRISM BioLab was the surviving entity and succeeded all PRISM Pharma's rights and obligations.In November 2020, PRISM BioLab entered into a multi-target research and licensing agreement with Merck, for screening against Merck’s research targets. Upon identification of hit compounds, Merck has an option to license and further develop the compounds. The company was eligible to receive undisclosed licensing payments, success-based milestone payments, and royalties on future sales.In September 2020, InveniAI collaborated with PRISM BioLab to identify and validate targets to develop therapies for gut-related diseas